| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethanol | 24 | 2022 | 893 | 2.950 |
Why?
|
| Alcohol Drinking | 15 | 2022 | 805 | 2.580 |
Why?
|
| Methylphenidate | 6 | 2014 | 97 | 1.690 |
Why?
|
| Motor Activity | 10 | 2015 | 621 | 1.690 |
Why?
|
| Caffeine | 3 | 2021 | 81 | 1.670 |
Why?
|
| Nucleus Accumbens | 14 | 2021 | 417 | 1.510 |
Why?
|
| Conditioning, Operant | 9 | 2017 | 241 | 1.420 |
Why?
|
| Energy Drinks | 2 | 2021 | 4 | 1.200 |
Why?
|
| Mice | 39 | 2022 | 8474 | 1.070 |
Why?
|
| Mice, Inbred C57BL | 24 | 2021 | 2791 | 0.970 |
Why?
|
| Alcoholism | 6 | 2022 | 1109 | 0.830 |
Why?
|
| Central Nervous System Stimulants | 3 | 2014 | 221 | 0.820 |
Why?
|
| Animals | 46 | 2022 | 20881 | 0.810 |
Why?
|
| Central Nervous System Depressants | 4 | 2015 | 182 | 0.720 |
Why?
|
| Cocaine | 8 | 2017 | 555 | 0.720 |
Why?
|
| Behavior, Animal | 6 | 2018 | 470 | 0.670 |
Why?
|
| Binge Drinking | 4 | 2021 | 50 | 0.640 |
Why?
|
| Extracellular Fluid | 4 | 2013 | 29 | 0.620 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2018 | 1745 | 0.610 |
Why?
|
| Drug Tolerance | 2 | 2015 | 80 | 0.610 |
Why?
|
| AIDS Dementia Complex | 3 | 2007 | 20 | 0.590 |
Why?
|
| Cocaine-Related Disorders | 5 | 2017 | 504 | 0.580 |
Why?
|
| Glutamic Acid | 5 | 2013 | 332 | 0.570 |
Why?
|
| Locomotion | 4 | 2017 | 135 | 0.560 |
Why?
|
| Choice Behavior | 2 | 2015 | 85 | 0.470 |
Why?
|
| Neurons | 5 | 2021 | 881 | 0.460 |
Why?
|
| Male | 38 | 2021 | 37321 | 0.450 |
Why?
|
| Alcoholic Beverages | 1 | 2012 | 18 | 0.430 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2005 | 154 | 0.430 |
Why?
|
| Reward | 3 | 2017 | 201 | 0.410 |
Why?
|
| Drug-Seeking Behavior | 4 | 2017 | 213 | 0.390 |
Why?
|
| Receptors, Opioid, kappa | 3 | 2022 | 37 | 0.380 |
Why?
|
| Self Administration | 10 | 2020 | 419 | 0.380 |
Why?
|
| Microdialysis | 6 | 2013 | 147 | 0.370 |
Why?
|
| Central Amygdaloid Nucleus | 2 | 2022 | 16 | 0.360 |
Why?
|
| Neuronal Plasticity | 3 | 2017 | 274 | 0.350 |
Why?
|
| Hippocampus | 3 | 2019 | 471 | 0.350 |
Why?
|
| Brain | 5 | 2019 | 2176 | 0.340 |
Why?
|
| Receptors, Muscarinic | 1 | 2009 | 44 | 0.340 |
Why?
|
| Motivation | 1 | 2012 | 561 | 0.320 |
Why?
|
| Axons | 1 | 2009 | 139 | 0.310 |
Why?
|
| Mice, SCID | 3 | 2007 | 238 | 0.310 |
Why?
|
| Cognition Disorders | 3 | 2007 | 342 | 0.300 |
Why?
|
| Oxytocin | 2 | 2021 | 124 | 0.300 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2019 | 124 | 0.290 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2007 | 30 | 0.290 |
Why?
|
| Recurrence | 4 | 2021 | 948 | 0.280 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 2550 | 0.260 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2005 | 9 | 0.260 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2005 | 52 | 0.260 |
Why?
|
| Neostriatum | 1 | 2005 | 60 | 0.260 |
Why?
|
| Microinjections | 5 | 2020 | 130 | 0.260 |
Why?
|
| Reflex, Startle | 1 | 2005 | 39 | 0.250 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 2004 | 2 | 0.250 |
Why?
|
| Herpesviridae Infections | 1 | 2004 | 23 | 0.250 |
Why?
|
| Drug Interactions | 4 | 2012 | 289 | 0.230 |
Why?
|
| Corpus Striatum | 3 | 2019 | 279 | 0.220 |
Why?
|
| Conditioning, Classical | 1 | 2003 | 57 | 0.220 |
Why?
|
| Analysis of Variance | 3 | 2015 | 1040 | 0.220 |
Why?
|
| Naltrexone | 2 | 2018 | 195 | 0.210 |
Why?
|
| Dynorphins | 2 | 2022 | 69 | 0.210 |
Why?
|
| Aging | 3 | 2011 | 911 | 0.200 |
Why?
|
| Fear | 1 | 2003 | 239 | 0.200 |
Why?
|
| Stress, Physiological | 1 | 2003 | 215 | 0.200 |
Why?
|
| Receptors, Oxytocin | 1 | 2021 | 9 | 0.190 |
Why?
|
| Sweetening Agents | 1 | 2021 | 23 | 0.190 |
Why?
|
| Ceftriaxone | 1 | 2021 | 32 | 0.190 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2021 | 26 | 0.190 |
Why?
|
| Dopamine | 3 | 2008 | 474 | 0.180 |
Why?
|
| Septal Nuclei | 1 | 2020 | 31 | 0.170 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 2018 | 5 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2019 | 114 | 0.160 |
Why?
|
| Dopamine Uptake Inhibitors | 4 | 2008 | 152 | 0.160 |
Why?
|
| Prefrontal Cortex | 3 | 2019 | 640 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 184 | 0.160 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2019 | 435 | 0.160 |
Why?
|
| Dendritic Spines | 2 | 2017 | 76 | 0.160 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 56 | 0.150 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2017 | 35 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 118 | 0.140 |
Why?
|
| Globus Pallidus | 1 | 2017 | 64 | 0.140 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2017 | 109 | 0.140 |
Why?
|
| Interneurons | 1 | 2017 | 70 | 0.140 |
Why?
|
| Pregnancy | 3 | 2009 | 2334 | 0.140 |
Why?
|
| Astrocytes | 2 | 2009 | 270 | 0.130 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2015 | 3 | 0.130 |
Why?
|
| KCNQ3 Potassium Channel | 1 | 2015 | 3 | 0.130 |
Why?
|
| Ataxia | 1 | 2015 | 11 | 0.130 |
Why?
|
| Gliosis | 2 | 2006 | 51 | 0.130 |
Why?
|
| Post-Synaptic Density | 1 | 2015 | 7 | 0.130 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 218 | 0.120 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2015 | 27 | 0.120 |
Why?
|
| Food Preferences | 1 | 2014 | 46 | 0.120 |
Why?
|
| Fatigue | 2 | 2006 | 132 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2017 | 415 | 0.120 |
Why?
|
| Proteome | 1 | 2015 | 87 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2019 | 447 | 0.120 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2013 | 20 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2016 | 276 | 0.110 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2014 | 79 | 0.110 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2013 | 64 | 0.110 |
Why?
|
| Aspartic Acid | 1 | 2013 | 65 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 207 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2017 | 2083 | 0.110 |
Why?
|
| Amino Acids | 1 | 2013 | 131 | 0.110 |
Why?
|
| Rats | 5 | 2017 | 5300 | 0.110 |
Why?
|
| Drug Synergism | 2 | 2012 | 260 | 0.110 |
Why?
|
| Female | 10 | 2020 | 38074 | 0.110 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2012 | 14 | 0.110 |
Why?
|
| Alcohol Deterrents | 2 | 2015 | 86 | 0.100 |
Why?
|
| 4-Aminobutyrate Transaminase | 1 | 2012 | 4 | 0.100 |
Why?
|
| Vigabatrin | 1 | 2012 | 8 | 0.100 |
Why?
|
| Swimming | 2 | 2019 | 38 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2015 | 954 | 0.100 |
Why?
|
| Synaptic Transmission | 2 | 2015 | 236 | 0.100 |
Why?
|
| Avoidance Learning | 1 | 2012 | 58 | 0.100 |
Why?
|
| Linear Models | 2 | 2015 | 521 | 0.090 |
Why?
|
| Self Report | 1 | 2012 | 371 | 0.090 |
Why?
|
| Students | 1 | 2012 | 233 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 567 | 0.090 |
Why?
|
| Tetrazolium Salts | 1 | 2009 | 36 | 0.090 |
Why?
|
| Carbachol | 1 | 2009 | 34 | 0.090 |
Why?
|
| Muscarinic Agonists | 1 | 2009 | 17 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2009 | 78 | 0.080 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Coloring Agents | 1 | 2009 | 66 | 0.080 |
Why?
|
| Thiazoles | 1 | 2009 | 95 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 659 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 175 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2016 | 1615 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2008 | 282 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2009 | 270 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2017 | 597 | 0.080 |
Why?
|
| Administration, Inhalation | 1 | 2008 | 187 | 0.080 |
Why?
|
| Taurine | 1 | 2008 | 51 | 0.080 |
Why?
|
| Ventral Tegmental Area | 1 | 2008 | 74 | 0.070 |
Why?
|
| Piperazines | 2 | 2008 | 206 | 0.070 |
Why?
|
| Maze Learning | 2 | 2007 | 138 | 0.070 |
Why?
|
| Estrous Cycle | 1 | 2007 | 23 | 0.070 |
Why?
|
| Individuality | 1 | 2007 | 44 | 0.070 |
Why?
|
| Reinforcement Schedule | 1 | 2007 | 59 | 0.070 |
Why?
|
| Chromatography, Gas | 1 | 2006 | 31 | 0.070 |
Why?
|
| Drinking Behavior | 1 | 2006 | 20 | 0.070 |
Why?
|
| Osmolar Concentration | 1 | 2006 | 134 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1174 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 73 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2008 | 156 | 0.070 |
Why?
|
| Animals, Newborn | 2 | 2007 | 396 | 0.070 |
Why?
|
| Cues | 1 | 2011 | 654 | 0.070 |
Why?
|
| Models, Psychological | 1 | 2007 | 180 | 0.070 |
Why?
|
| Sucrose | 1 | 2005 | 58 | 0.070 |
Why?
|
| Microglia | 1 | 2006 | 143 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 1242 | 0.060 |
Why?
|
| Tritium | 1 | 2005 | 101 | 0.060 |
Why?
|
| Radioligand Assay | 1 | 2005 | 109 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2005 | 165 | 0.060 |
Why?
|
| Potassium Channel Blockers | 2 | 2015 | 32 | 0.060 |
Why?
|
| Humans | 7 | 2017 | 68618 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2007 | 295 | 0.060 |
Why?
|
| Acoustic Stimulation | 1 | 2005 | 206 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2005 | 1692 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 1033 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2673 | 0.060 |
Why?
|
| Pyridines | 1 | 2005 | 261 | 0.060 |
Why?
|
| Corticosterone | 1 | 2003 | 51 | 0.060 |
Why?
|
| Receptors, AMPA | 2 | 2017 | 99 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2003 | 106 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2003 | 131 | 0.050 |
Why?
|
| Catheterization | 1 | 2003 | 209 | 0.050 |
Why?
|
| Survivors | 1 | 2004 | 256 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 1664 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2006 | 1330 | 0.050 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2021 | 15 | 0.050 |
Why?
|
| Esterification | 2 | 2011 | 25 | 0.050 |
Why?
|
| Administration, Cutaneous | 2 | 2011 | 56 | 0.050 |
Why?
|
| Algorithms | 1 | 2007 | 1196 | 0.050 |
Why?
|
| Hypothalamus | 1 | 2021 | 78 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2015 | 765 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 286 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2011 | 411 | 0.040 |
Why?
|
| Biological Availability | 2 | 2011 | 79 | 0.040 |
Why?
|
| Genetic Techniques | 1 | 2018 | 32 | 0.040 |
Why?
|
| Models, Animal | 1 | 2019 | 252 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2019 | 190 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 32 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2018 | 312 | 0.040 |
Why?
|
| Actin Cytoskeleton | 1 | 2017 | 37 | 0.040 |
Why?
|
| Somatostatin | 1 | 2017 | 36 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 44 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2017 | 83 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2017 | 59 | 0.040 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2017 | 51 | 0.040 |
Why?
|
| Organ Culture Techniques | 1 | 2017 | 122 | 0.030 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2017 | 128 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 4655 | 0.030 |
Why?
|
| Sumoylation | 1 | 2015 | 4 | 0.030 |
Why?
|
| Taste Perception | 1 | 2015 | 7 | 0.030 |
Why?
|
| Phenylenediamines | 1 | 2015 | 16 | 0.030 |
Why?
|
| Anthracenes | 1 | 2015 | 26 | 0.030 |
Why?
|
| Alcohol Withdrawal Seizures | 1 | 2015 | 12 | 0.030 |
Why?
|
| Membrane Transport Modulators | 1 | 2015 | 23 | 0.030 |
Why?
|
| Apamin | 1 | 2015 | 13 | 0.030 |
Why?
|
| Carbamates | 1 | 2015 | 41 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 35 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 120 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 63 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 166 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 139 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2015 | 204 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2015 | 371 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 714 | 0.030 |
Why?
|
| Genomics | 1 | 2015 | 168 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2015 | 218 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2015 | 223 | 0.030 |
Why?
|
| Computational Biology | 1 | 2015 | 190 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2017 | 617 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 780 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2019 | 824 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 1426 | 0.020 |
Why?
|
| Skin Absorption | 1 | 2011 | 7 | 0.020 |
Why?
|
| Transdermal Patch | 1 | 2011 | 21 | 0.020 |
Why?
|
| Isomerism | 1 | 2011 | 63 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2011 | 59 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 2011 | 41 | 0.020 |
Why?
|
| Biotransformation | 1 | 2011 | 69 | 0.020 |
Why?
|
| Reserpine | 1 | 2008 | 24 | 0.020 |
Why?
|
| Raclopride | 1 | 2008 | 15 | 0.020 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2008 | 15 | 0.020 |
Why?
|
| Dopamine D2 Receptor Antagonists | 1 | 2008 | 13 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2008 | 48 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2008 | 87 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 89 | 0.020 |
Why?
|
| Dialysis | 1 | 2007 | 30 | 0.020 |
Why?
|
| Quinoxalines | 1 | 2008 | 78 | 0.020 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2008 | 87 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2007 | 120 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2008 | 203 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 238 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 150 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 5731 | 0.020 |
Why?
|
| Memory | 1 | 2007 | 214 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 329 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 381 | 0.020 |
Why?
|
| Homer Scaffolding Proteins | 1 | 2004 | 24 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 626 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 7277 | 0.010 |
Why?
|
| Macrophages | 1 | 2007 | 647 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 532 | 0.010 |
Why?
|
| Cognition | 1 | 2007 | 513 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 1864 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 1266 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 14862 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 1641 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 21147 | 0.010 |
Why?
|